$AbCellera Biologics(ABCL)$ $M-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Fabian MacDonald
10-26

$AbCellera Biologics(ABCL)$ $Moderna, Inc.(MRNA)$ $Pfizer(PFE)$ $Eli Lilly(LLY)$ $SELLAS Life Sciences Group Inc.(SLS)$ $AbCellera Biologics(ABCL)$ The squeeze potential here is real, at least from where I stand. The stock had 23.6% of the float short and 9.7 days to cover. That likely came after the company moved from a service-for-fee model to betting entirely on themselves, while others were positioned against the Q2 print.

Latest insider buys:

- CFO Andrew Booth bought 37,200 shares at $10.32, roughly $384K.

- Director John Montalbano bought 10,000 shares at $11.03, roughly $110K.

- Hayden bought 46,387 shares at $10.37, roughly $481K.

No insider selling over the latest 6 months, and the data readout has been solid so far as management tightens the quarterly burn rate. I'm betting the daily wedge plays out, and I've put my money where my mouth is. Next objective would be breaking $12.86, then finally testing that $15 level.

I'm going all in again on management taking this home.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":622285589184512,"tweetId":"622285589184512","gmtCreate":1792962314000,"gmtModify":1793007255445,"author":{"id":10000000000010952,"idStr":"10000000000010953","authorId":10000000000010952,"authorIdStr":"10000000000010953","name":"Fabian MacDonald","avatar":"https://static.tigerbbs.com/7a01996bb0eadab44875ad885eaeabea","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/e5578e6861fc487fb04e06d589c438a3","width":"1206","height":"821"},{"img":"https://community-static.tradeup.com/news/d3a8ae336594435ea24d180ed394f9b9","width":"1189","height":"972"},{"img":"https://community-static.tradeup.com/news/35ee7888e64e4ec48d249e253226a017","width":"1200","height":"1200"},{"img":"https://community-static.tradeup.com/news/e73d5038a5604f4f8924dabf21bbf97b","width":"1100","height":"1200"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/e5578e6861fc487fb04e06d589c438a3","width":"1206","height":"821"},{"img":"https://community-static.tradeup.com/news/d3a8ae336594435ea24d180ed394f9b9","width":"1189","height":"972"},{"img":"https://community-static.tradeup.com/news/35ee7888e64e4ec48d249e253226a017","width":"1200","height":"1200"}],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/ABCL\">$AbCellera Biologics(ABCL)$&nbsp;</a><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$&nbsp;</a><a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$&nbsp;</a><a href=\"https://ttm.financial/S/SLS\">$SELLAS Life Sciences Group Inc.(SLS)$&nbsp;</a><a href=\"https://ttm.financial/S/ABCL\">$AbCellera Biologics(ABCL)$&nbsp;</a>The squeeze potential here is real, at least from where I stand. The stock had 23.6% of the float short and 9.7 days to cover. That likely came after the company moved from a service-for-fee model to betting entirely on themselves, while others were positioned against the Q2 print.</p>\n<p>Latest insider buys:</p>\n<p>- CFO Andrew Booth bought 37,200 shares at $10.32, roughly $384K.</p>\n<p>- Director John Montalbano bought 10,000 shares at $11.03, roughly $110K.</p>\n<p>- Hayden bought 46,387 shares at $10.37, roughly $481K.</p>\n<p>No insider selling over the latest 6 months, and the data readout has been solid so far as management tightens the quarterly burn rate. I'm betting the daily wedge plays out, and I've put my money where my mouth is. Next objective would be breaking $12.86, then finally testing that $15 level.</p>\n<p>I'm going all in again on management taking this home.</p>\n<p><img src=\"https://community-static.tradeup.com/news/e5578e6861fc487fb04e06d589c438a3\" tg-width=\"1206\" tg-height=\"821\"></p>\n<p><img src=\"https://community-static.tradeup.com/news/d3a8ae336594435ea24d180ed394f9b9\" tg-width=\"1189\" tg-height=\"972\"></p>\n<p><img src=\"https://community-static.tradeup.com/news/35ee7888e64e4ec48d249e253226a017\" tg-width=\"1200\" tg-height=\"1200\"></p>\n<p><img src=\"https://community-static.tradeup.com/news/e73d5038a5604f4f8924dabf21bbf97b\" tg-width=\"1100\" tg-height=\"1200\"></p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/ABCL\">$AbCellera Biologics(ABCL)$&nbsp;</a><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$&nbsp;</a><a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$&nbsp;</a><a href=\"https://ttm.financial/S/SLS\">$SELLAS Life Sciences Group Inc.(SLS)$&nbsp;</a><a href=\"https://ttm.financial/S/ABCL\">$AbCellera Biologics(ABCL)$&nbsp;</a>The squeeze potential here is real, at least from where I stand. The stock had 23.6% of the float short and 9.7 days to cover. That likely came after the company moved from a service-for-fee model to betting entirely on themselves, while others were positioned against the Q2 print.</p>\n<p>Latest insider buys:</p>\n<p>- CFO Andrew Booth bought 37,200 shares at $10.32, roughly $384K.</p>\n<p>- Director John Montalbano bought 10,000 shares at $11.03, roughly $110K.</p>\n<p>- Hayden bought 46,387 shares at $10.37, roughly $481K.</p>\n<p>No insider selling over the latest 6 months, and the data readout has been solid so far as management tightens the quarterly burn rate. I'm betting the daily wedge plays out, and I've put my money where my mouth is. Next objective would be breaking $12.86, then finally testing that $15 level.</p>\n<p>I'm going all in again on management taking this home.</p>\n<p><img src=\"https://community-static.tradeup.com/news/e5578e6861fc487fb04e06d589c438a3\" tg-width=\"1206\" tg-height=\"821\"></p>\n<p><img src=\"https://community-static.tradeup.com/news/d3a8ae336594435ea24d180ed394f9b9\" tg-width=\"1189\" tg-height=\"972\"></p>\n<p><img src=\"https://community-static.tradeup.com/news/35ee7888e64e4ec48d249e253226a017\" tg-width=\"1200\" tg-height=\"1200\"></p>\n<p><img src=\"https://community-static.tradeup.com/news/e73d5038a5604f4f8924dabf21bbf97b\" tg-width=\"1100\" tg-height=\"1200\"></p></body></html>","text":"$AbCellera Biologics(ABCL)$ $Moderna, Inc.(MRNA)$ $Pfizer(PFE)$ $Eli Lilly(LLY)$ $SELLAS Life Sciences Group Inc.(SLS)$ $AbCellera Biologics(ABCL)$ The squeeze potential here is real, at least from where I stand. The stock had 23.6% of the float short and 9.7 days to cover. That likely came after the company moved from a service-for-fee model to betting entirely on themselves, while others were positioned against the Q2 print. Latest insider buys: - CFO Andrew Booth bought 37,200 shares at $10.32, roughly $384K. - Director John Montalbano bought 10,000 shares at $11.03, roughly $110K. - Hayden bought 46,387 shares at $10.37, roughly $481K. No insider selling over the latest 6 months, and the data readout has been solid so far as management tightens the quarterly burn rate. I'm betting the daily wedge plays out, and I've put my money where my mouth is. Next objective would be breaking $12.86, then finally testing that $15 level. I'm going all in again on management taking this home.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/622285589184512","repostId":0,"isVote":1,"tweetType":1,"viewCount":339,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["SLS","LLY","MRNA","ABCL","PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":838,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}